How to Induce Insulin Resistance In Vitro
Four protocols
| Protocol | Working concentration | Duration | Mechanism | Reversibility |
|---|---|---|---|---|
| Chronic insulin | 100 nM, serum-free or low-serum | 16–24 h | IR/IRS-1 downregulation | 24–48 h after withdrawal |
| Palmitate | 100–400 µM, BSA-conjugated, 6:1 molar | 16–24 h | DAG–PKCθ, ceramide, ER stress | Slow, incomplete |
| Cytokine | TNF-α 10 ng/mL, or 50% macrophage-conditioned medium | 24 h | SOCS induction, phosphatase activation | Partial |
| High glucose | 25–30 mM | 48–72 h | Hexosamine flux, osmotic and methylglyoxal stress | Slow; partly selection |
Each produces a different molecular state. Reporting "we induced insulin resistance with palmitate" and "we induced it with insulin" as the same manipulation is the most common source of non-reproducibility in this literature.
Important distinction. The chronic insulin protocol is desensitisation. It is the easiest to perform, the most reversible, and the least representative of human insulin resistance, in which signalling is impaired at normal receptor density.
Palmitate: the concentration is not the concentration
Palmitate is insoluble and is delivered bound to fatty-acid-free BSA. The biologically relevant quantity is the free fatty acid concentration, which depends on the molar ratio of fatty acid to albumin, not on the nominal concentration added.
| Parameter | Practical value | Why |
|---|---|---|
| BSA | Fatty-acid-free, ≥ 98% | Residual fatty acids in normal BSA dominate at low palmitate |
| Molar ratio | 3:1 to 6:1 (FA:BSA) | Higher ratios give higher free concentration and more precipitation |
| Conjugation | Dissolve palmitate in ethanol or NaOH at 70 °C, then add to BSA solution at 37 °C | Direct addition to medium precipitates |
| Filtration | 0.22 µm after conjugation | Removes crystals that otherwise act as phagocytic particles |
| Vehicle control | BSA at the same molar concentration | BSA alone alters lipid availability and signalling |
Caveat on the vehicle. BSA binds and delivers lipids from serum, and it adsorbs to surfaces. A BSA-only control is not a null control; it is a low-level lipid exposure. The correct comparison is BSA-matched, and the difference between BSA and no-BSA is itself an effect.
The readout: a dose–response, not a single point
- Serum-starve 4–6 h (not overnight — overnight starvation itself reduces insulin signalling).
- Stimulate with insulin at 0, 0.1, 1, 10, 100 nM for 10 min at 37 °C.
- Lyse directly in hot SDS buffer; phosphatases are fast and cold lysis is not fast enough for some sites.
- Blot for p-AKT T308, p-AKT S473, total AKT, and the upstream node that the model is supposed to affect (IRS-1, IRβ).
- Fit the dose–response and report EC₅₀ and maximum, not a fold-change at one concentration.
| Result | Interpretation | Follow-up |
|---|---|---|
| Right shift, same maximum | Reduced sensitivity | Receptor-proximal mechanism; check IRS-1/IR |
| Lower maximum, same EC₅₀ | Reduced capacity | Check GLUT4 content, signalling machinery abundance |
| Both | Mixed | Report both parameters |
Readout note. A single 10 nM point cannot separate these. At 10 nM, a right-shifted curve and a flattened curve both give a reduced signal, and the two imply different targets.
Functional confirmation
Signalling is a proxy. The functional readouts differ by cell type:
| Cell type | Functional readout | Note |
|---|---|---|
| Myotube | 2-DG uptake ± insulin; glycogen | 2-DG is not linear with transport rate |
| Adipocyte | 2-DG uptake; glycerol release ± isoproterenol | Lipolysis suppression is insulin action too |
| Hepatocyte | Glucose output; de novo lipogenesis | Measure both — hepatic resistance is selective |
Important distinction. In hepatocytes, the two arms diverge: glucose output becomes resistant while lipogenesis remains insulin-sensitive or increases. A protocol that reduces p-AKT uniformly has produced a state that does not match the human hepatic phenotype, and reporting only glucose output will hide it.
Controls that are usually missing
- • Osmotic control for high glucose: 25 mM mannitol or L-glucose.
- • Vehicle-matched BSA for palmitate.
- • Time-matched, insulin-free control for the chronic insulin protocol — the cells have been in culture the same number of days.
- • Washout arm to establish reversibility, which distinguishes desensitisation from toxicity.
- • Viability at the end: palmitate at 400 µM kills cells in some lines, and dead cells do not signal.
- • Confluence and passage recorded: both change basal and stimulated uptake.
Reporting checklist
Six items make the experiment reproducible:
- Cell type, passage, and confluence at treatment.
- Serum concentration during treatment and during starvation.
- Inducer, concentration, vehicle, and duration.
- Insulin concentrations used and stimulation time.
- The phosphorylation sites blotted, with total-protein controls.
- EC₅₀ and maximum for the dose–response, with n and replicate definition.
Failures that recur
- • 100 nM insulin used as "stimulation" rather than as the induction protocol. At that concentration, sensitivity differences saturate.
- • Overnight starvation. It reduces insulin signalling by itself.
- • Palmitate added directly to medium. It precipitates.
- • No BSA control. The vehicle is a treatment.
- • Total GLUT4 blotted to assess translocation. Total is usually unchanged.
- • p-AKT S473 only. mTORC2-dependent and confounded by any mTOR effect.
Where this connects
- • Insulin resistance models article supplies the interpretation layer: which of the three states each protocol produces.
- • Lipid pillar supplies the palmitate handling rules, including the BSA ratio.
- • Disease pillar supplies the tissue frame: the same protocol means different things in myotube, adipocyte and hepatocyte.
Scientific interpretation and experimental design
- • Name the mechanism, not just the inducer. Desensitisation, lipid interference and cytokine signalling are different.
- • Report the free fatty acid ratio. Nominal concentration is not exposure.
- • Run a dose–response. EC₅₀ and maximum are the result.
- • Include a washout arm. Reversibility distinguishes adaptation from injury.
- • Match the functional readout to the cell type.
- • Measure both hepatic arms. Resistance is selective.
Selected references for further reading
- • Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiological Reviews. 2018;98:2133–2223.
- • Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 2006;440:944–948.
- • Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature. 2019;576:51–60.
- • Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017;169:381–405.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »